Conversely, in 2022, Ytterberg et al. conducted the Oral Rheumatoid Arthritis Trial (ORAL) Surveillance trial [167], aiming at evaluating the safety and efficacy of tofacitinib compared with anti-TNF in patients with rheumatoid arthritis who were 50 years of age or older and had at least one additional cardiovascular risk factor. This evidence concerns the gene TNF and rheumatoid arthritis.